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Abstract
Background: Transurethral resection of the prostate (TURP) has been the standard operation for benign prostatic
obstruction (BPO) for 40 years, with approximately 25,000 procedures performed annually, and has remained largely
unchanged. It is generally a successful operation, but has well-documented risks for the patient. Thulium laser
transurethral vaporesection of the prostate (ThuVARP) vaporises and resects the prostate using a surgical technique
similar to TURP. The small amount of study data currently available suggests that ThuVARP may have certain
advantages over TURP, including reduced blood loss and shorter hospital stay, earlier return to normal activities,
and shorter duration of catheterisation.
Design: A multicentre, pragmatic, randomised, controlled, parallel-group trial of ThuVARP versus standard TURP in
men with BPO. Four hundred and ten men suitable for prostate surgery were randomised to receive either
ThuVARP or TURP at four university teaching hospitals, and three district general hospitals. The key aim of the trial is
to determine whether ThuVARP is equivalent to TURP judged on both the patient-reported International Prostate
Symptom Score (IPSS) and the maximum urine flow rate (Qmax) at 12 months post-surgery.
(Continued on next page)
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Discussion: The general population has an increased life expectancy. As men get older their prostates enlarge,
potentially causing BPO, which often requires surgery. Therefore, as the population ages, more prostate operations
are needed to relieve obstruction. There is hence sustained interest in the condition and increasing need to find
safer techniques than TURP. Various laser techniques have become available but none are widely used in the NHS
because of lengthy training required for surgeons or inferior performance on clinical outcomes. Promising initial
evidence from one RCT shows that ThuVARP has equivalent clinical effectiveness when compared to TURP, as well
as other potential advantages. As ThuVARP uses a technique similar to that used in TURP, the learning curve is
short, potentially making it also very quickly generalisable. This randomised study is designed to provide the
high-quality evidence, in an NHS setting, with a range of patient-reported, clinical and cost-effectiveness outcomes,
which will underpin and inform future NICE guidance.
Trial registration: ISRCTN registry, ISRCTN00788389. Registered on 20 September 2013.
Keywords: UNBLOCS, Prostate, Surgery, Lower urinary tract symptoms, Benign prostatic obstruction, Randomised
controlled trial, Transurethral resection of the prostate, TURP, Thulium laser transurethral vaporesection of the
prostate, ThuVARP
Background
The prostate gland sits at the exit of the bladder like a
collar, and as men get older their prostates enlarge. This
can commonly result in either urinary retention, an in-
ability to completely empty the bladder, or in bother-
some lower urinary tract symptoms (LUTS) secondary
to benign prostatic obstruction (BPO), such as slow and
intermittent urinary stream. These conditions severely
affect a man’s quality of life resulting in worsening phys-
ical and social functioning, vitality, and mental health
[1]. Bothersome LUTS secondary to BPO with an Inter-
national Prostate Symptom Score (IPSS) of at least 11
and a maximum urine flow rate (Qmax) less than 15 ml/
s affects 2.5 million men aged 40–79 in the UK, with
44,000 new cases diagnosed annually [2]. LUTS may be
treated by watchful waiting or drugs, but many will re-
quire prostate surgery, including almost all men who
present in urinary retention.
Around 25,000 prostate operations are performed an-
nually in the UK for men with BPO to relieve obstruc-
tion. Transurethral resection of the prostate (TURP), the
gold standard operation, accounts for around 80% of
these operations. TURP has been used widely for the last
40 years, and although it is generally a successful pro-
cedure, it is associated with small but significant risks. It
has a 30-day mortality of 0.3%, and a range of morbid-
ities including transurethral resection (TUR) syndrome
(1%), which is due to the absorption of irrigating fluid
leading to confusion and collapse; haemorrhage during
the operation (transfusion rate: 5%); and subsequent
urinary tract infections (up to 20%) [3]. These morbid-
ities result in delayed discharge and increased re-
admissions, increased primary care resource utilisation,
considerable distress to patients and additional costs to
the National Health Service (NHS).
The well-known risks for both mortality and morbidity
from TURP have meant that many alternatives have
been assessed. Various laser alternatives have been mar-
keted, but none have become widely used. This is due,
in part, to a long learning curve, or inferior performance
regarding clinical outcomes, reducing the wider uptake.
In fact, Hospital Episode Statistics (HES) data shows
that the percentage of laser procedures has only in-
creased in England by 2% over the past 5 years, from
2894 in 2009/10 to 2958 in 2011/12. This is despite the
accepted advantages of laser prostatectomy, including
lower risk of peri-operative complications, shorter cath-
eterisation time and reduced hospital stay [4]. Recent
National Institute for Health and Care Excellence
(NICE) clinical guidelines CG97 recommend offering
TURP or holmium laser enucleation (HoLEP) for BPO
surgery [5]. Although HoLEP is a long-established effect-
ive procedure, it is only used in a few centres, due to a
very long learning curve reducing its generalisability,
and indeed NICE recommends that this procedure is
only performed in centres specialising in the technique.
This study, UriNary oBstruction relieved by Laser Or
Conventional Surgery (UNBLOCS), is evaluating a new
laser technique called thulium laser transurethral vapore-
section of the prostate (ThuVARP). A thulium laser tech-
nique has been chosen which vaporises and resects the
prostate because it uses a surgical technique similar to
TURP, and will therefore enable a short learning curve
making it quickly generalisable. It was first made available
in 2004 in the UK but has only been compared in one ran-
domised controlled trial (RCT) in China against TURP
[6]. Based on this RCT and one non-randomised prospect-
ive controlled trial with small and medium-sized prostates
[7], the European Association of Urology (EAU) guidelines
have stated that ThuVARP showed equivalent efficacy in
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comparison with TURP [8]. However the thulium patients
had shorter catheterisation and hospitalisation times,
with adverse events being lower than for TURP
(intra-operative and post-operative bleeding; level of
evidence 1b).
NICE in its 2010 Male LUTS Guidelines [5] stated that
the evidence base is inadequate to give clear guidance in
terms of clinical and cost effectiveness of laser vapore-
section techniques. NICE identified that research in this
area, in the form of a randomised controlled trial, would
help inform future guidance on the use of laser vapore-
section techniques for men with LUTS or urinary reten-
tion, who need surgery.
Rationale for the trial
The general population has an increased life expectancy,
resulting in an ageing population. As BPO is a disease of
older men, the number of patients with the condition is
expected to grow by almost 50% by the year 2025, in-
creasing the need for BPO surgery [2]. Furthermore, as
the operation is increasingly conducted on older men
(42% of the TURP operations in 2014–2015 were on pa-
tients older than 75 years), the risks of surgery associ-
ated with TURP will continue to increase. There is
therefore sustained interest in the condition and increas-
ing need to find safer techniques than TURP. The po-
tential advantages of reduced blood loss, shorter hospital
stay and earlier return to normal activities make laser
vaporesection techniques attractive to both patients and
health care providers. ThuVARP would allow urologists
to operate on a wider range of men, including potentially
those who are more frail and older, but with less risk.
However, there is uncertainty about the degree of symp-
tom improvement and improvement in quality of life in
the short and longer term, which this trial addresses.
Now is the ideal time to conduct the trial as the proced-
ure has not yet been widely taken up across the UK.
An additional reason for early evaluation of ThuVARP is
the promise it offers to convert BPO surgery from an in-
patient operation into a day-case procedure. Shortened
stay is increasingly important for the NHS both because
of the increasing cost of inpatient beds, shortage of in-
patient beds due to an ageing and increasingly co-morbid
population, and the risk longer hospital stays present for
such patients, for example of hospital-acquired infections.
In summary, although there is little existing work
on ThuVARP, promising initial evidence from one
RCT suggests that ThuVARP has equivalent clinical
effectiveness when compared to TURP, albeit in a sin-
gle Chinese centre. Our randomised study is designed
to provide the high-quality evidence, in an NHS set-
ting with a range of patient-reported, clinical and
cost-effectiveness outcomes, which will underpin and
inform future NICE guidance.
Methods/trial design
Study aims and objectives
The key aim of this research is to determine whether
ThuVARP is equivalent to TURP in men with BPO
treated within the NHS, judged on a patient-reported
symptom severity score (IPSS) and the maximum urine
flow rate (Qmax).
We will answer the following primary question: what
is the relative clinical effectiveness of ThuVARP and
TURP in improving patient-reported LUTS as measured
by the International Prostate Symptom Score (IPSS)
patient-reported questionnaire, and the objective meas-
ure of maximum urine flow rate (Qmax), 12 months
after surgery?
Secondary research questions are:
1. How do the two procedures compare in terms of
peri-operative outcomes?
2. What is the cost-effectiveness of ThuVARP as com-
pared to TURP in terms of the two primary out-
comes and quality-adjusted life years (QALYs: the
primary economic outcome)?
3. What is the comparative impact of each treatment
on patient-reported LUTS, erectile function, quality
of life and general health?
4. What is the comparative satisfaction of men with
each type of surgery?
5. What is the comparative effectiveness of these
operations in men who present with LUTS as
opposed to urinary retention?
6. What are men’s experiences of both procedures,
including those presenting with LUTS or urinary
retention?
Trial design
This is a multicentre, pragmatic, randomised, controlled,
parallel-group trial of thulium laser transurethral vapor-
esection of the prostate (ThuVARP) versus standard
transurethral resection of the prostate (TURP) in men
with benign prostatic obstruction (BPO). Randomisation
is at the patient level so men were randomised 1:1 to re-
ceive either ThuVARP or TURP.
This study is powered to establish equivalence in clin-
ical improvement. We are specifying differences in
Qmax and IPSS of no greater than 4 ml/s and 2.5 units
respectively, as demonstrating equivalence.
Follow-up is at 6 weeks, 3 and 12 months after surgery
for the patient-reported outcome (PRO) IPSS, and at 3 and
12 months for the maximum urine flow rate (Qmax), with
12 months being the primary endpoint. Patients are asked
to complete other patient-reported outcomes at 6 weeks
after surgery (by post), and after 3 and 12 months. The
study flow diagram is provided in Fig. 1 and the Standard
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Protocol Items: Recommendations for Interventional Trials
(SPIRIT) checklist in Additional file 1.
Setting
Participants have been recruited and operated on at
seven UK centres: four university teaching hospitals and
three district general hospitals. Each of the centres in
the trial performs between 150 and 400 benign prostate
operations per year.
Study duration
Recruitment for the trial began in June 2014 and com-
pleted at the end of December 2016. Twelve-month
follow-up for all participants will complete by the end of
November 2017.
Participants
As this is a pragmatic trial, it includes men who are suitable
for TURP referred to secondary care for assessment with a
view to requiring BPO surgery, presenting with either
bothersome LUTS or urinary retention secondary to BPO.
Inclusion criteria
 Men who were suitable for TURP, either in urinary
retention or with bothersome LUTS, secondary to
BPO.
Fig. 1 Study flow diagram. BPO benign prostatic obstruction, CRF case report form, PVR post-void residual, ThuVARP thulium laser transurethral
vaporesection of the prostate, TURP transurethral resection of the prostate
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Exclusion criteria
Patients with:
 Neurogenic LUTS
 Prostate cancer
 Previous prostate or urethral surgery
 A prostate-specific antigen (PSA) outside of the nor-
mal age-related range and who had not had prostate
cancer excluded
 Men who were unable to give informed consent or
complete trial documentation
Interventions
Patients were randomised 1:1 to receive either the TURP or
ThuVARP procedure. As this is a pragmatic study, centres
continued to use their usual practices, for example, with re-
spect to whether or not they did pressure-flow urodynamics
as part of patient selection, or how they undertook the
TURP procedure, e.g. use of monopolar or bipolar TURP.
All trial surgeons underwent training on the ThuVARP
technique as described below.
Patients undergoing concomitant procedures during
their BPO surgery were included in the trial, and details
of their additional surgery recorded.
All adverse events are recorded and serious adverse
events notified to the appropriate authorities (Research Eth-
ics Committee and Sponsor) within specified timelines.
Surgeon training on the laser
ThuVARP uses laser technology to vaporise and resect
the prostate while TURP uses electric current to resect
the prostate. ThuVARP essentially uses the same surgical
skill-set as for the TURP procedure which is part of core
practice for all urologists, including trial surgeons who
performed both procedures. The experience of the Chief
Investigator and other urologists, in the UK and Europe,
indicate that a maximum of 15 ThuVARP laser cases can
assure competence in the ThuVARP laser procedure.
All surgeons were mentored by the Chief Investiga-
tor (CI) or another Principal Investigator (PI) already
certified as competent with the ThuVARP technique,
and certified by an independent assessor, using stand-
ard criteria, before the official study commenced.
First, surgeons observed the CI/PI performing one to
two cases. The CI/PI then observed the surgeons in
each centre perform two to five cases during site
visits. The surgeons then performed five to ten cases
without supervision, following their respective Trust’s
clinical governance and audit guidelines. Competency
was assessed with the Intercollegiate Surgical Curricu-
lum Programme work-based assessment (ISCP-WBA)
by an independent assessor. If competency was not
achieved at this stage, then further cases would have
been observed and training provided by the CI until
the competency criteria were met, however in practice
all surgeons were signed off as competent at their
first assessment.
Withdrawal
Participants remain in the trial unless they choose to
withdraw or if they are unable to continue for a clin-
ical reason. If a participant withdraws consent, partici-
pant questionnaires are not collected. However,
permission is sought for the research team to continue
to collect outcome data from their health care records.
Participants are informed in the Patient Information
Sheet (PIS) that they have the right to withdraw all
personal data held by the study, but otherwise this
data is retained.
Outcome measures
Two key co-primary outcomes were selected, measured
at 12 months, based on a well-established and validated
patient-reported outcome (PRO), the International Pros-
tate Symptom Score (IPSS) [9], and the urodynamic clin-
ical measure of maximum urine flow rate (Qmax: ml/s)
which is used in all BPO trials. These outcomes address
the primary research question for the trial.
The IPSS and Qmax are internationally accepted,
and the most frequently used primary outcomes in
BPO studies, thereby making results from this study
comparable to others. There are no core outcomes
measures for BPO listed in the COMET Initiative
website.
Key secondary outcome measures include other well-
validated PROs and answer the trial research questions:
1. Clavien-Dindo classification of surgical
complications [10]
2. Length of hospital stay and transfusion rates
3. International Consultation on Incontinence
Questionnaire – Male Lower Urinary Tract
Symptoms (ICIQ-MLUTS) (for symptom bother)
4. International Index of Erectile Function (IIEF) and
ICIQ-MLUTSsex (measures of erectile function)
5. ICIQ-LUTSqol (condition-specific quality of life
score)
6. EuroQol Group’s five-dimension health status ques-
tionnaire (EQ-5D-5L) (preference-based general
quality of life measure)
7. ICIQ-satisfaction (measures satisfaction with surgery
outcomes) to assess the full impact of the
intervention on patients and the NHS
8. Resource use for the year following randomisation to
inform the cost-effectiveness analysis
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9. Interviews following surgery, for qualitative analysis
of men’s experiences of both procedures
In addition to these key secondary outcomes, other
secondary outcomes are:
1. Post-operative catheterisation time
2. Haemoglobin (blood loss during surgery)
3. Serum sodium (absorption of irrigation fluid)
4. Post-void residual urine
Assessment and follow-up
The timing of our outcome measurements are sum-
marised in Fig. 2 (schedule of enrolment, interventions,
and assessments) and described below.
Clinical outcomes
Urine flow rate (Qmax), post-void residual (PVR) and
voided volume (VV) were measured before surgery in
men who were able to void without a catheter. The most
recent existing measures were used if they were performed
Fig. 2 Schedule of enrolements, interventions and assessments
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within 90 days of informed consent. PVR and VV were
measured post-operatively, and Qmax, PVR and VV at 3
and 12 months post-surgery. These follow-up flow mea-
sures are not collected if men are catheterised, but trial
without catheter (TWOC) data is recorded.
Blood parameters were also measured at baseline and
post-operatively, including full blood count (FBC) and
urea and electrolytes (U&Es).
Patient reported outcomes
Participants receive the UNBLOCS Symptoms/Surgery
Questionnaire at baseline in clinic, 6 weeks post-surgery
(by post), and at 3 and 12 months post-surgery in clinic
(with the option to take home and return in pre-paid en-
velope if preferred). The questionnaire contains ques-
tions from standardised outcome instruments for
urinary and sexual symptoms (listed in Fig. 2) and the
baseline questionnaire had versions for men who were
using a catheter and those who were not, as some items
were not relevant for catheterised patients. Participants
who are catheterised at the time of the 3- or 12-month
questionnaires are instructed to only answer the ques-
tions that they feel able to. The Bladder Diary was given
to participants at their baseline clinic and at their 3 and
12 months clinics if they do not require a catheter to
void at the time. The Bladder Diary is used to record
fluid intake, frequency and volume of micturition and
bladder sensation and use of pads over 3 days, and is
returned in a pre-paid envelope.
Economic data collection
Details of initial hospital stay resource use, e.g. operation
duration; operating staff; consumables; the time spent in
recovery; length of stay on different wards; overall length
of stay and treatment for complications, were collected
on study-designed case report forms (CRFs) by the re-
search nurse at the time of the inpatient/day-case stay
for the initial surgery. Hospital patient-linked informa-
tion costing systems are used if available to capture
follow-up hospital use at the treating hospital. If this in-
formation cannot be accessed then subsequent inpatient
stays, outpatient visits and procedures occurring at the
treating hospitals are abstracted from the patients’ med-
ical records and recorded on a CRF.
On discharge from hospital, and at 3 months follow-
up the patients are given a study designed Resource Use
Log (RUL) to be used as an aide memoire in which to
record NHS and private community-based health care
use, other NHS hospital health care use, medications,
personal social service (PSS) resource use in addition to
travel, time off work/usual activities and any other ex-
penses resulting from their treatment [11]. These logs
reflect the design of the 3-month and 12-month
UNBLOCS Resource Use questionnaire. At 3 months
and 12 months follow-up, participants are able to use
the information from the RUL in order to complete the
UNBLOCS Resource Use Questionnaire, which they take
home from clinic, or receive by post along with a pre-
paid return envelope. The EQ-5D-5L will be used to cal-
culate quality-adjusted life years (QALYs). The new five-
level EQ-5D is used in preference to the three-level one,
owing to its improved discriminatory power [12].
Qualitative data collection
The main aims of the qualitative component, which is being
investigated with in-depth semi-structured interviews with
participants at between 3 and 6 months post-surgery are:
1. To explore patient experiences of ThuVARP and
TURP
2. To explore determinants of patient satisfaction with
the two procedures
3. To identify any differences in experience between
men presenting with LUTS or urinary retention.
The basis of the interview schedule/topic guide is fo-
cused around these three themes and further informed by
the literature and clinical experience of the co-applicants,
but will also allow participants to address issues or con-
cerns of particular relevance to their own experience. In-
terviews have been targeted at 3 to 6 months post-surgery
to allow recovery from the operation and return to daily
activities whilst also permitting good recall of the experi-
ence of the procedures and immediate sequelae.
Participants from both the ThuVARP and TURP inter-
vention arms are recruited to take part in exploratory in-
terviews. Study participants who provide consent to
being approached for qualitative interviews are purpos-
ively selected to represent the two surgical interventions,
two presentations for surgery (LUTS and urinary reten-
tion) and demographic characteristics such as age. This
is included to better understand the differences between
the two surgical procedures in terms of the individuals’
lived experience. In particular, the interview schedule fo-
cuses on the immediate experience surrounding surgery
and features of the continued recovery and effects on
daily life. This is important to capture contextual data to
support interpretation and contextualisation of the trial
quantitative outcomes.
Participants are also asked to articulate what their ex-
pectations of surgery were prior to the procedure and
upon which factors they judged their perceived satisfac-
tion, or dissatisfaction subsequent to the operation, and
whether this was a dynamic or static decision that al-
tered during the recovery period. This aspect of the in-
vestigation will focus on capturing both clinical and
non-clinical determinants of satisfaction which will be
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linked to the quantitative analyses for interpreting the
outcomes e.g. quality of life.
Sample size
This study is powered to establish equivalence in clinical
improvement. The Chinese trial [6] observed differences
of 0.4 ml/s (95% CI: -2.0 to 2.8) in Qmax and 0.4 units
(-0.7 to 1.5) in IPSS between ThuVARP and TURP. Vari-
ability (standard deviation; SD) in data at 12 months was
approximately 6.0 ml/s (Qmax) and 3.0 units (IPSS), but
previous trials of TURP report greater variability, around
9 ml/s (Qmax) and 5 units IPSS [13, 14].
We have specified differences of 4 ml/s in Qmax and
2.5 units in IPSS, as demonstrating equivalence. Equiva-
lence studies often use an alternative hypothesis of a dif-
ference of zero between treatments. However, the
Chinese trial observed differences of around 0.4 ml/s
and 0.4 units for Qmax and IPSS. Incorporating these as
alternative hypotheses ensures adequate power to dem-
onstrate equivalence if treatments are indeed similar but
not identical.
Assuming SDs of 9 ml/s for Qmax and 5 units for
IPSS, the target sample size for patients needed to
complete the 12-month follow-up was 163 patients in
each group. Using NQuery Advisor, this will provide
85% power to demonstrate equivalence for Qmax and
just over 90% power for IPSS, at a two-sided alpha of
5%. Assuming 20% loss to follow-up following random-
isation, it was necessary to recruit 410 men in total. This
loss to follow-up is a conservative estimate from our ex-
perience of previous trials. However, we are aiming to
reduce loss to follow-up through letter, text and tele-
phone reminders to patients.
Randomisation
All men who entered the trial were logged with the cen-
tral study office and given a unique, six-digit study (par-
ticipant) identification number.
Participants were randomly allocated to treatment
arms using an automated web/telephone randomisation
system provided by the Bristol Randomised Trials Col-
laboration (BRTC). This took place in the anaesthetic
room when the patient was anaesthetised.
Randomisation was stratified by centre and whether
the patient was eligible due to bothersome LUTS or
urinary retention, and random blocking was employed
(of two, four and six randomly allocated).
Blinding
To reduce bias in the assessment of outcomes, partici-
pants were not informed of their study arm allocation,
although their general practitioner (GP) can access this
information. Participants were informed that, although it
would be preferred that they did not know which
operation they have had; their GP will not be prevented
from giving them this information if they request it. We
anticipated that some men will ask for, or discover, their
allocation at some point during the study and we will be
asking them to reveal when and how they became aware
of this in the 12-month follow-up questionnaire. Partici-
pants will be informed of the type of BPO surgery they
received after receipt of their 12-month follow-up ques-
tionnaires and Bladder Diary, or 1 month after they have
received a reminder for these.
Statistical analysis
All data analysis will be in accordance with the Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
lines extension for non-inferiority and equivalence trials
[15]. A full statistical analysis plan will be developed and
agreed by the Data Monitoring Committee and the Trial
Steering Group prior to undertaking any analyses of the
trial data.
Descriptive statistics will be used to compare patient
baseline characteristics between the two treatment
groups. The primary comparative analyses will be con-
ducted on an ‘as allocated’ basis and will employ multi-
variable linear regression to investigate equivalence in
Qmax and IPSS between ThuVARP and TURP at
12 months. Analyses will adjust for stratification vari-
ables (centre and retention). Interpretation of results will
focus on observed differences, and 95% confidence inter-
vals for the between-group comparisons, to determine
whether clinically important differences between Thu-
VARP and TURP are unlikely. Missing data will be im-
puted using multiple imputation modelling. Additional
sensitivity analysis will explore the impact of missing
data by using complete cases only. Sensitivity analyses
will also consider adjustment for baseline measures of
Qmax and IPSS (with clinically sensible values imputed
for those with retention, for example a Qmax of zero)
any variables demonstrating imbalance at baseline. Con-
sideration will also be given to surgeon effects using
mixed-effects models.
As randomisation will occur close to the time of
surgery, a significant cross-over between treatment
groups is thought unlikely, but any departures from
protocol are likely to make the treatment groups
more similar. In a superiority trial an ‘as allocated’
(or intention-to-treat) analysis is a conservative ap-
proach. In an equivalence trial, such as this, where
the objective is to demonstrate that treatments have a
similar effect, a per protocol analysis may be a more
conservative approach, but prone to bias. An alterna-
tive is randomisation-based efficacy estimators (com-
plier average causal effect models (CACE)) which
maintain randomisation [16]. If protocol deviations
occur we will conduct sensitivity analyses to assist
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with the interpretation of the primary result, these
will include CACE and per protocol analyses with
discussion of any likely bias in the resulting estimates.
Analyses of secondary analyses will employ linear, lo-
gistic or multinomial regression models as appropriate.
Repeated measure models will explore any treatment-
time interactions considering the 6 weeks and 3 months
data in addition to baseline and 12 months. Potential ef-
fect modifiers, selected a priori and informed by previ-
ous evidence, will be explored using formal tests or
interaction. These will include:
 Clinical diagnosis at baseline of LUTS secondary to
BPO or urinary retention (stratification variable)
 Pre-operative prostate size measured by digital rectal
examination
 Age
 Patient co-morbidities at baseline (Charlson Comor-
bidity Index)
 Conduct of TURP procedures; whether monopolar
or bipolar TURP
 Length of stay of procedures; including whether
day-case or inpatient
Interpretation will focus on the confidence intervals
only and will be hypothesis-generating since the trial is
not powered for such analyses. No interim analyses are
planned.
Economic data analysis
The trial includes a formal economic evaluation compar-
ing the costs and cost-effectiveness of the interventions
from an NHS and broader societal perspective (with per-
sonal social service and patient costs reported separ-
ately). Only resources used in relation to the treatment
of LUTS, or urinary retention secondary to BPO, will be
analysed from randomisation at the time of surgery, to
12 months follow-up. The cost of the interventions and
the use of primary and secondary NHS services by the
men, personal and social service costs, costs to the men
arising from their treatment (e.g. travel, over-the-
counter medication) and productivity costs will be esti-
mated through the collection of resource-use data as
outlined earlier and the valuation of these data.
Micro-costing of the initial hospital stay will be needed
and therefore Trust finance departments of the partici-
pating hospitals will be approached in order to value the
initial NHS resources used. All other resource use will
be valued using information from the laser company,
routine sources and information from the patients
themselves.
The EQ-5D-5L is administered at baseline and at
6 weeks, 3 and 12 months after the operation. These
values will be transformed into utility scores [17] and
individual QALYs will be calculated using the area under
the curve approach.
Initially, regression techniques adjusting for pre-
specified baseline characteristics, randomisation vari-
ables and a centre effect will be used to evaluate the dif-
ference in costs. Boot-strapped confidence intervals will
be used, given the potential non-normality of the cost
data. The same model will be used to evaluate the differ-
ence in QALYs. The differences in terms of the two pri-
mary outcomes will be evaluated according to the
statistical analysis plan.
For the base case economic analysis, for the two per-
spectives, cost-effectiveness will be assessed using the Net
Benefit framework over a range of values for the QALY.
A secondary economic analysis, for the two perspec-
tives, will be conducted in which the outcomes will be
the co-primary outcomes of the trial (i.e. IPSS and urine
flow, Qmax). For this analysis the differences in costs
and effects will be examined. If one arm is dominant (i.e.
less costly and more effective) no further incremental
analysis will be conducted. Otherwise an incremental
cost-effectiveness ratio (ICER) will be calculated. Seem-
ingly unrelated regressions (SUR) will be used, if appro-
priate, to account for the potential correlation between
costs and the IPSS score/Qmax values.
Uncertainty will be addressed using cost-effectiveness
acceptability curves and sensitivity analyses. One aspect
of uncertainty is likely to be that of missing data. As
with the main analysis, a pre-specified analysis plan will
be created in which the plausible assumptions about
missing data will be created and tested using these as-
sumptions within the sensitivity analyses.
Additionally the costs of surgeon training for the Thu-
VARP laser technique will be estimated. This will be re-
ported to allow policy makers to more accurately
estimate the costs of service reconfiguration if the Thu-
VARP laser is shown to be equivalent to the TURP.
These costs will also be incorporated in one of the sensi-
tivity analyses.
No modelling has been specified within this evalu-
ation, as the work is seen as a definitive trial, and experi-
ence has shown that most uncertainty in relation to cost
differences will be captured within the first 12 months,
the duration of this trial.
Qualitative data analysis
A standardised approach will be employed to explore
the interview data in accordance with published qualita-
tive research methods. Face-to-face patient interviews
will be conducted where possible, with telephone inter-
views included for other study sites, which will be car-
ried out by an experienced qualitative researcher.
Interviews will be digitally recorded, transcribed verba-
tim and uploaded into a qualitative software package to
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aid data management (QSR NVivo 10). Analyses will be
conducted by the qualitative researcher according to the
principles of thematic content analysis. Recordings will
be listened to and transcripts read and re-read for famil-
iarisation. Segments of text will be ‘coded’ by assigning
descriptive labels. Codes will be grouped on the basis of
shared properties to create themes, and coded tran-
scripts will then be examined and compared to induct-
ively refine and delineate themes (constant comparison).
A subset of interviews will be independently analysed by
a second study researcher and coding discrepancies dis-
cussed to maximise rigour and reliability. Plausibility of
data interpretation will be further discussed between the
study team, including the clinical co-applicants,
throughout the analyses. Descriptive summary accounts
of the interviews will be prepared.
Theoretical purposive (non-probability) sampling will
be used, where explanations, developing to describe the
data during analyses, guide further sampling and data
collection. Maximum variation sampling will also ensure
the diverse characteristics of the population are sampled
(e.g. participants varying in age, clinical history and sur-
gery received). Sampling and analyses will continue in it-
erative cycles until no new themes are emerging and
established themes cease evolving: data saturation. It is
anticipated that approximately 30–40 participants will
be required, with up to 20 per procedure to allow for
sampling of those with LUTS and urinary retention as
the reason for their treatment.
Discussion
This article describes a multicentre randomised trial to
compare ThuVARP to the current gold standard TURP
surgery for benign prostatic obstruction. The aim is to
determine the relative clinical and cost effectiveness of
the two alternative procedures, within the NHS.
The most significant challenge for the trial, during the
recruitment phase, has been the capacity of participating
Trusts to undertake the required surgery. Randomisation
occurs in the operating theatre whilst the patient is
under anaesthetic. Operating theatre availability and
hospital bed pressures within Trusts, particularly during
the winter months, slowed recruitment for this elective
procedure, despite a ready pool of willing participants.
Protected research operating time secured at two partici-
pating Trusts, the advent of day case procedures and
multiple surgeons at sites, helped to overcome these
challenges, albeit with additional time for recruitment
required. It should be noted that the very difficulties ex-
perienced in conducting this trial, with the shortage of
hospital beds impacting on the capacity for Trusts to op-
erate, are the very same issues which ThuVARP has the
promise to address, with its potential for shorter hospital
stays, and shift to day case procedures.
This randomised study will provide the high-quality
evidence, in an NHS setting with a range of patient-
reported, clinical and cost-effectiveness outcomes, which
will underpin and inform future NICE guidance in a
timely manner.
Trial status
The UNBLOCS trial began recruitment in June 2014,
with the first participant enrolled on 23 July 2014. Re-
cruitment completed on 31 December 2016.
Additional file
Additional file 1: SPIRIT checklist. (DOC 121 kb)
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